Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 5/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.43 |
| ▸ | IDH1 | O75874 | 4/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.41 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1974468 | 0.91 | PTGES (0.57) | PTGESHPGDHDAC6IDH1TP53 | |
| SCHEMBL3705491 | 0.90 | PTGES (0.48) | PTGESHPGDHDAC6IDH1TP53 | |
| SCHEMBL1972843 | 0.87 | PTGES (0.57) | PTGESHPGDHDAC6IDH1TP53 | |
| SCHEMBL1969251 | 0.86 | PTGES (0.54) | PTGES | |
| SCHEMBL16318489 | 0.86 | PTGES (0.54) | PTGES | |
| SCHEMBL1974764 | 0.84 | PTGES (0.50) | PTGESHPGDHDAC6TP53POLB | |
| SCHEMBL16318485 | 0.83 | PTGES (0.49) | PTGESHPGDHDAC6TP53POLB | |
| SCHEMBL13392918 | 0.81 | PTGES (0.57) | PTGESHPGDHDAC6TP53MAPK14 | |
| SCHEMBL16352184 | 0.80 | TP53 (0.56) | HPGDHDAC6TP53POLBMAPT | |
| SCHEMBL1968497 | 0.80 | TP53 (0.56) | HPGDHDAC6TP53POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2334652-A1 | 1H-BENZ IMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | Boehringer Ingelheim International GmbH (DE) | 2011-06-22 | — | — | EP | claimed |
| WO-2010034796-A1 | 1H-BENZ IMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | claimed |
| US-20150011513-A1 | ALKYNE-, AZIDE- AND TRIAZOLE-CONTAINING FLAVONOIDS AS MODULATORS FOR MULTIDRUG RESISTANCE IN CANCERS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2015-01-08 | — | — | US | disclosed |
| US-8916599-B2 | 1H-benz imidazole-5-carboxamides as anti-inflammatory agents | OREXO AB (SE) | 2014-12-23 | — | — | US | disclosed |
| US-8916599-B2 | 1H-benz imidazole-5-carboxamides as anti-inflammatory agents | OREXO AB (SE) | 2014-12-23 | — | — | US | disclosed |
| US-20110312935-A1 | 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| US-20110312935-A1 | 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312935-A1 | 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents | MAPRE2, MAPRE1, H1-4 | PTGES 118/4885HPGD 1009/4885HDAC6 177/4885 |
| US-20150011513-A1 | ALKYNE-, AZIDE- AND TRIAZOLE-CONTAINING FLAVONOIDS AS MODULATORS FOR MULTIDRUG RESISTANCE IN CANCERS | ABCG2, ABCB1, ABCC1 | PTGES 3823/4885HPGD 3409/4885HDAC6 2954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.